VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
about
Pathway analysis with next-generation sequencing data.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa iTyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
P2860
Q30834583-B17913A9-06E6-41B6-9E7D-DA60885FDABEQ36755620-B63F30C8-9808-4514-BFDB-BDA8E95661E8Q38201503-792EC668-E902-40F4-9387-D792E28E4FCDQ38693165-3FEDBA86-EE31-4F0B-960C-59EB3069AAAAQ38813467-98FF3E12-3F69-4589-A513-F799EFA26D1FQ39348099-F5532DE4-325F-479F-B743-617B6D3E1E3BQ42364404-1E94C94E-99F2-429E-A203-78B47CFB9DDE
P2860
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@en
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@nl
type
label
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@en
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@nl
prefLabel
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@en
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@nl
P2093
P2860
P1476
VEGF pathway inhibition by ant ...... rosclerosis plaque disruption.
@en
P2093
François Goldwasser
Olivier Mir
Olivier Vignaux
Stanislas Ropert
P2860
P2888
P304
P356
10.1007/S10637-010-9500-9
P577
2010-07-30T00:00:00Z